FORM 3
        	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
	OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5	
                      	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	                      	

1. Name and Address of Reporting Person *

Andrews William T.	2. Date of Event Requiring Statement (MM/DD/YYYY)
10/2/2017 
	3. Issuer Name and Ticker or Trading Symbol

Acer Therapeutics Inc. [ACER]	
(Last)        (First)        (Middle)

C/O ACER THERAPEUTICS INC., 222 THIRD STREET, SUITE #2240	4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
Chief Medical Officer /	
(Street)

CAMBRIDGE, MA 02142       

(City)              (State)              (Zip)	5. If Amendment, Date Original Filed (MM/DD/YYYY)

	6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned	
1.Title of Security
(Instr. 4)	2. Amount of Securities Beneficially Owned
(Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)	4. Nature of Indirect Beneficial Ownership
(Instr. 5)	

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)	
1. Title of Derivate Security
(Instr. 4)	2. Date Exercisable and Expiration Date
(MM/DD/YYYY)	3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)	6. Nature of Indirect Beneficial Ownership
(Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:	

Remarks:
Exhibit List: Exhibit 24 - Power of Attorney	
No securities are beneficially owned.	

Reporting Owners	
Reporting Owner Name / Address	Relationships	
	Director	10% Owner	Officer	Other	
Andrews William T.
C/O ACER THERAPEUTICS INC.
222 THIRD STREET, SUITE #2240
CAMBRIDGE, MA 02142			Chief Medical Officer		

Signatures		
/s/ William T. Andrews		10/6/2017	
** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).	
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.	

 
CONFIRMING STATEMENT
 
This Statement confirms that the undersigned has authorized and designated each of Chris Schelling and Harry Palmin (each an “ attorney-in-fact ” ), each acting singly, to execute and file or cause to be filed on the undersigned's behalf a Form ID and all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Acer Therapeutics Inc. The undersigned hereby grants to each attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do personally present, with full power of substitution, resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney ’ s-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The authority of each attorney-in-fact under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned ’ s ownership of or transactions in securities of Acer Therapeutics Inc. unless earlier revoked in writing. The undersigned acknowledges that none of the attorneys-in-fact are assuming any of the undersigned ’ s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.
 
This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned ’ s filing obligations with respect to securities of Acer Therapeutics Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.
 
Dated: October 6, 2017                                                                             
Signed: /s/ Andrew T. Williams                                                                  
 
Print Name: Andrew T. Williams